© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Cefpirome sulfate belongs in the fourth generation of cephalosporin antibiotics, meaning scientists built on decades of antimicrobial research to get here. Early cephalosporins emerged in the 1960s, but microbial resistance kept pushing researchers to keep adapting these drugs. Early cephalosporins lacked punch against Gram-negative bacteria and kept falling short as new resistant strains cropped up. Eventually, chemists tuned side chains and altered core structures in labs throughout the 1980s and 1990s to find more versatile molecules. Cefpirome came out of these efforts, offering a broad activity spectrum, particularly against pathogens notorious for hospital-acquired infections. Its development echoes the relentless pace of resistant bugs meeting smarter drug engineering.
Cefpirome sulfate now serves hospitals and clinics worldwide as an injectable broad-spectrum antibiotic. Formulated as a white or nearly white crystalline powder, it comes packed in sterile vials for intravenous use. This formulation means the drug can go straight into systemic circulation, ensuring high peak tissue levels—essential for battling entrenched infections. The packaging information sets clear reconstitution instructions and storage conditions, keeping hospital pharmacy errors low and the product safe until use. Cefpirome sulfate’s chemical strength shows up not just on lab slides but in real-world recoveries after stubborn bacterial attacks.
Cefpirome sulfate usually appears as a stable, fine powder—almost odorless, quite soluble in water, and slightly soluble in ethanol. Its molecular formula gets cited as C22H22N6O5S2, with a molecular weight hovering around 566 (for the base compound). As a sulfate salt, the crystalline form holds up well under refrigerated storage, rarely showing signs of degradation if kept dry and protected from light. These physical traits matter for high-volume hospital use, where both stability and quick solubility are crucial. The chemical backbone owes much to cephalosporin’s celebrated beta-lactam ring, but additional groups on the molecule boost its effect against resistant bacteria and help it survive attack by beta-lactamase enzymes.
Vial labels outline cefpirome content, expiration dates, batch numbers, and instructions for dilution with sterile water. Dosing information rarely leaves much guesswork, detailing recommended doses by age, weight, and infection type. Clear warnings identify contraindications such as allergy to cephalosporins and highlight the need for dose adjustment in those with kidney impairment. Manufacturing certificates track the chain of production for pharmacovigilance—and batch traceability means side-effect reports can be checked against specific lots. Data sheets include assay and purity minimums (often ≥98% by HPLC), pH ranges for solutions, and guidelines for temperature and humidity limits, all essential for building trust with pharmacists and clinicians.
Manufacturers produce cefpirome using fermentation-derived cephalosporin intermediates. After complex multi-step synthesis featuring acylation, reduction, and protective group manipulations, scientists crystallize out the sulfate salt form. Purification involves repeated extraction, chromatography, and filtration steps, designed to eliminate impurities and potential allergens. The preparation lines up with Good Manufacturing Practice (GMP) standards, and each batch undergoes full characterization by spectroscopic and chromatographic methods. Once complete, the sterile powder heads into sealed vials in facilities with clean air systems, reducing the chance of contamination. These steps show how much human effort goes into every therapeutic vial that reaches a patient.
Cefpirome’s chemistry reflects ongoing attempts to outwit bacterial resistance. Researchers routinely explore small tweaks to the side chain at the 7-position of the cephalosporin nucleus, since this spot dramatically impacts activity. Sulfoxide formation and strategic placement of heterocyclic rings on the molecule fine-tune its pharmacological bite against tough strains. Reaction protocols highlight acylation and rearrangement methods to strengthen resistance to beta-lactamase enzymes. Such modifications do more than fill journal articles; they drive clinical breakthroughs, giving infectious disease doctors another chance in battles against multidrug-resistant threats. It’s a never-ending arms race with bacteria, fought on the level of a few atoms at a time.
Cefpirome sulfate goes by a handful of names depending on country and manufacturer. The chemical literature sometimes calls it “Cefpirome Monosulfate,” “HR 810,” or “Cefpirome Sulphate.” Trade names like “Cefrom,” “Cefromin,” “Keiten,” and others surface on pharmacy shelves worldwide. Regulatory filings use the International Nonproprietary Name (INN), sticking to “cefpirome.” Hospitals track these names for accurate inventory, especially when national regulations or tender systems dictate which synonym appears on labels. In my own time spent in pharmacy, getting the right drug in the right hands often meant digging through these overlapping names to confirm the match.
No hospital can afford mistakes with high-potency antibiotics. Administrators follow strict protocols for storage, handling, and disposal—requiring refrigeration in secure, temperature-monitored spaces. Only trained staff prepare and administer cefpirome, checking allergy histories to avoid cross-reactions in patients sensitive to penicillins or other cephalosporins. Administration through a controlled infusion ensures that the patient receives the correct dose at a safe rate. Hospitals thread a tight needle between delivering enough medicine to cure infection and avoiding side effects like allergic reactions, diarrhea, or kidney impacts. Regulatory authorities audit suppliers for GMP compliance, focusing especially on cross-contamination risks and lot traceability. These safety practices don’t just meet legal minimums; they underpin every patient’s hope for safe, effective recovery.
Clinical teams reach for cefpirome sulfate during tough infections—hospital-acquired pneumonia, severe urinary tract infections, and complicated skin infections, among others. Infectious disease specialists value its activity against hard-to-kill organisms like Pseudomonas aeruginosa and some Enterobacteriaceae. Cefpirome’s value shows up in high-risk patients, such as those with compromised immune systems or intensive care unit stays. Its ability to cut down on mortality from stubborn Gram-negative infections is more than theoretical; countless case studies tell the stories. Like many older clinicians, I remember the early days of using fourth-generation agents as a last resort. Now stewardship programs guard their use, reserving them for confirmed or strongly suspected multidrug-resistant infections to slow the march of further resistance.
Antibiotic pipeline research never stops. Scientists and doctors keep analyzing cefpirome’s action, effectiveness compared to rival agents and potential synergies with other drugs. Studies dig into mechanisms behind emerging resistance, investigating how changes in bacterial cell walls or production of powerful enzymes blunt cefpirome’s punch. Ongoing trials test new dosing regimens and explore combination therapies, working to maximize clinical success and hold down side effects. Global antibiotic shortages make researchers look again at older, proven drugs like cefpirome with renewed urgency, hoping for backup when newer options run dry. Each wave of superbugs sends researchers back to the lab, trying to keep classic molecules viable a little longer.
Every new antibiotic runs a gauntlet of toxicity studies before reaching patients. For cefpirome, animal and human trials measured kidney and liver impacts, hypersensitivity reactions, and potential for superinfection, particularly by Clostridium difficile. Monitoring blood counts and renal function in trials, scientists mapped out safe treatment windows and recognized dosing pitfalls. Most patients handle cefpirome without serious issues, but clinicians commit to careful monitoring—especially in those with pre-existing allergies or renal impairment. Years of pharmacovigilance continue to uncover rare but serious reactions, alerting practitioners to warning signs. Careful labeling, ongoing research, and practitioner education form the triple lock for safe use.
Cefpirome sulfate stands at a crossroads, challenged by both evolving resistance and global shortages of newer antibiotics. The world’s appetite for hospital antibiotics keeps growing, and supply chains face stress from regulatory changes and pandemic disruptions. Next-generation cephalosporins and combination therapies aim to fill gaps, but each new agent must prove its worth in patient bedsides, not just in the lab. Pharmacoeconomic analysis supports keeping proven options like cefpirome in the arsenal, especially for severe infections resistant to first-line options. Stewardship programs and advanced diagnostic tools will play a bigger role, matching antibiotic to pathogen more precisely and limiting indiscriminate use. Investment in basic research remains vital, from discovering new cephalosporin analogues to tracking global resistance trends. No one drug wins the war on infection alone—but by building on the lessons of cefpirome, the next generation of antibiotics can push outcomes further and help doctors turn desperate cases into success stories.
Cefpirome sulfate falls into the family of fourth-generation cephalosporin antibiotics. Hospitals and doctors trust it to handle some of the toughest bacterial infections. Bugs like Pseudomonas aeruginosa, Enterobacter, and Staphylococcus aureus don't respond to ordinary antibiotics. Cefpirome steps in when nothing seems to work. Its chemical power knocks down bacteria that show resistance to older drugs.
Antibiotic resistance keeps rising. The World Health Organization flagged resistant infections as a top global threat to public health. People who’ve spent time in hospitals, especially in ICUs, are most at risk. I’ve seen patients bounce between several antibiotics, getting sicker each round. Families wonder if there’s still hope. Cefpirome sulfate becomes a lifeline in those moments when others don’t offer results.
Doctors rely on lab results before turning to cefpirome. It holds a reputation as a last defense, so it's not handed out freely. This approach helps slow resistance from spreading even faster. Overuse of broad-spectrum antibiotics only fuels a tougher enemy.
Cefpirome sulfate comes as an injection. The IV route means doctors reserve it for serious hospital cases. Pneumonia, sepsis, complicated urinary tract infections, and infections from burns often call for something robust. Infections after surgery or involving catheters sometimes don’t budge without it. Infection teams keep close tabs on side effects and kidneys during treatment. The powerful bacteria-killing action helps, but it isn’t risk-free.
Modern research backs up cefpirome’s use. A study published in the Journal of Antimicrobial Chemotherapy highlighted its strong results against Gram-negative bacteria. Nosocomial pneumonia—hospital-acquired lung infection—responds well, especially when other cephalosporins or penicillins fail. Clinical guidelines often mention it as an option for life-threatening cases.
Doctors know resistance varies by country and even by city. Antibiograms help guide the call on using cefpirome sulfate. Every year, labs track patterns of resistance to see if drugs are still working. In some places, resistance has crept up, which makes stewardship even more important.
Uncontrolled use of cefpirome means bacteria could soon outsmart it. Some hospitals have seen this with carbapenems, losing their effect within a decade. Cefpirome should be shielded from overuse. Only confirmed, life-threatening infections that resist other options should get this level of drug. Stewardship programs that require infectious disease approval make a difference. Training and tracking antibiotic use can protect these vital treatments for the most severe cases.
Pharmaceutical exploration still looks for the next wave of antibiotics. Resistance builds up faster than new treatments reach patients. Every dose counts. Using cefpirome sulfate responsibly gives people a genuine shot at beating deadly infections today, and hopefully tomorrow’s options will expand.
Cefpirome sulfate stands as a heavy hitter among fourth-generation cephalosporin antibiotics. Hospitals rely on it to tackle stubborn infections, from pneumonia to sepsis. With any drug this strong, the stakes run high, especially in how it gets delivered to the patient. Every detail counts — from dose and timing to the way the drug enters the bloodstream.
Cefpirome sulfate hits the mark best through intravenous routes, either direct injection or slow drip infusion. Oral pills never made it to the pharmacy shelves for this one, because the body can’t soak it up through the gut efficiently. Every time I watched a nurse prep the IV line, that sense of precision always stuck with me. Nobody grabs any random vein and hopes for the best; nurses take time, aiming for good access and steady flow, reducing the risk of phlebitis and ensuring the whole dose gets where it needs to go.
Infusion over 20 to 30 minutes helps patients avoid the sharp sting that rapid IV pushes can sometimes cause. With antibiotics like this, slow and steady isn’t just a saying — it’s a practice that saves tissue from unnecessary irritation and gives the body a fair shot at distribution. Most adult patients end up with a dose around 1 to 2 grams every twelve hours, adjusted according to the doctor’s call, severity of infection, or kidney function. Kids follow a similar pattern, but the numbers shrink relative to their weight.
Giving an antibiotic like cefpirome sulfate is never “one-and-done.” There’s always the chance of allergic reactions, kidney strain, or shifts in white blood cell counts. Every time a patient gets this drug, someone should keep an eye on signs of rash, trouble breathing, or swelling. Measuring the patient’s kidney function before the first dose makes sure the drug doesn’t build up to dangerous levels. Infections can cloud the picture, so every clue — fever, redness, or lab results — helps steer the therapy in a safer direction.
Hospital patients aren’t cookie-cutter. Some people battle infections right after surgery; others have chronic kidney problems or weak immune systems. Adjusting the dosing and infusion method isn’t just textbook advice; it’s standard practice. A doctor looking at a patient with reduced kidney function might lower the dose or space it out more, reducing the risk of toxicity. Multidrug-resistant bacteria sometimes demand higher doses or combination therapy. Clinicians don’t stick to rigid routines; they pivot based on evolving lab results and patient response.
The more staff know about cefpirome sulfate, the fewer mistakes slip through. Training nurses and doctors to double-check doses and watch for side effects makes a big difference. Electronic medical records flag dose errors or allergies, guiding safer decisions. Good communication, from pharmacy to bedside, helps spot errors before the drug drips in. These aren’t abstract ideas — tight teamwork keeps real people safe.
Patients can also play their part. Asking about strange rashes, reporting any new symptoms, or sharing their past drug allergies builds a complete safety net. Real-world experience, reliable guidelines, and steady teamwork form the backbone of any safe, effective administration of cefpirome sulfate, ensuring patients get what they need, and nothing they don’t.
Cefpirome sulfate shakes up bacteria when regular antibiotics no longer do the trick. Doctors like it for hospital infections where stakes run high and treatment options shrink. After hearing from folks who've taken this drug and sifting through research, I’ve seen patterns in how bodies react. Most people barely notice a thing, but for others, even standard antibiotics can come with bumps in the road.
The gut often speaks up first. Nausea, loose stools, and abdominal cramps seem to pop up more often than anyone wants to admit. Some studies say about one in ten patients sees these problems. Clostridium difficile infection sometimes becomes a bigger headache, which means a simple stomach ache can turn serious fast. Keeping an eye on your body’s signals helps. No one should ignore diarrhea that won’t quit, especially after a hospital stay.
Rashes and itching show up with almost every antibiotic, and cefpirome sulfate joins the club. Most rashes stay mild and fade away, but patients still notice them and, for many, they become worrying. In rare cases, more extreme allergic reactions storm in, with swelling or breathing problems. Immediate care makes all the difference here, since waiting can turn risky.
Doctors ask for more blood tests after starting cefpirome. White blood cell counts can drop, and platelets sometimes take a dive. This can sneak up with no symptoms at all, making those routine blood draws more important than they seem. Lab changes could pile on risk, making it hard to fight other infections or slowing healing. Catching drops early lets doctors swap medications fast.
Even the kidneys and liver have something to say about cefpirome. Most people pull through without issue, but those who already have problems there should expect closer checks. Creatinine and liver enzymes sometimes spike, which means these organs feel the stress. Nurses usually spot trouble before symptoms show up, but anyone with unusual fatigue, yellow skin, or dark urine should speak up.
Doctors and nurses make all the difference. Good communication saves lives. Reporting anything odd—hives, breathing trouble, unusual tiredness—can stop side effects early. Patients with allergies or chronic health problems should tell their healthcare team right away, since previous reactions raise the risks.
Using cefpirome sulfate safely relies on teamwork. Doctors pay close attention to patient history, monitor test results, and explain possible signs to watch for. Patients play their part by asking questions and sharing all changes they notice. Trust and transparency build confidence—and often, better health outcomes. In my own experience, being open about even small symptoms has caught problems before they exploded into emergencies.
People can make smarter choices when they understand what medicines bring to the table, both good and bad. Sharing experiences helps the next patient walk a smoother path. Recognizing possible side effects isn’t about fear—it's about protecting health in a world where superbugs force tough choices. Knowledge works best when shared out loud and used together, not kept behind clinic doors.
Cefpirome sulfate enters the scene when tough bacterial infections don’t back down with the usual antibiotics. It’s part of the cephalosporin family, which has saved countless lives. While this drug can turn the tide in serious infections, it can also pose serious challenges. People sometimes forget that all antibiotics, especially those in the hospital setting, bring potential complications.
Some people run into trouble with cefpirome right from the start. Anyone with a history of allergic reactions to cephalosporins or other beta-lactam antibiotics faces a real risk. People with allergies to penicillins sometimes land in the emergency room after severe cross-reactions. Hives, breathing trouble, and full-blown anaphylaxis demand attention—these are not worries to brush off.
Older adults and those with kidney problems face extra hurdles. Cefpirome, just like many antibiotics, exits the body through the kidneys. If those organs aren’t doing their job, the drug levels can rise quickly and cause unwanted effects. In practice, we check kidney function first and adjust doses for safety. I’ve seen this overlooked when wards are busy—patients then develop seizures or confusion.
Another problem comes from the fact that antibiotics don’t care if bacteria are harmful or helpful. After several days on cefpirome, a person’s normal bacteria might get wiped out, leaving space for resistant bugs or fungi. I remember working a night shift where a patient on broad-spectrum antibiotics developed severe diarrhea. Turned out he had Clostridioides difficile colitis, a direct result of disturbed gut flora. Nobody wants an infection traded for another, sometimes nastier, one.
Medications can clash. Adding cefpirome to the mix can affect how the kidneys handle other drugs, especially strong diuretics or certain antibiotics. I saw a patient’s kidney function drop after he received high-dose cefpirome with loop diuretics. Blood tests caught the damage early, and we swapped medicine. It’s easy to miss these details in the middle of a busy shift, but they make a huge difference.
Blood disorders like low platelets, low white blood cells, or anemia sneak up on patients after days of treatment. Some folks just start bruising easily, or their infections linger for longer than expected. Regular lab checks during therapy pick up these issues before they get worse.
Cefpirome doesn’t get prescribed lightly these days, with rising worries about antibiotic resistance. Medical teams need to sort out which infections genuinely deserve such a broad-spectrum weapon. Hospitals now run antibiotic stewardship rounds to catch overuse and counsel doctors. I’ve sat through these reviews: it’s never about blame, but about not making a difficult problem harder.
People also play a role in their own care—reporting allergies, listing all medications, and asking questions about side effects. I always encourage patients to flag any new problems right away.
The safest approach with cefpirome starts with clear communication, careful checking, and regular follow-up. Every nurse, pharmacist, and physician who pauses to double-check helps keep stubborn infections from turning into bigger problems. In an era of complex medicine, real safety comes from people watching out for each other.
Pregnancy can turn even a trip to the pharmacy into a stressful event. Many people hope antibiotics will save the day when infections threaten. Doctors reach for a broad set of tools, and cefpirome sulfate pops up as a strong contender in tough cases. It’s a powerful, fourth-generation cephalosporin, usually reserved for severe infections like sepsis, lower respiratory tract infections, or life-threatening urinary tract infections.
Doctors avoid using medications during pregnancy unless the safety profile looks rock solid. Cefpirome has helped save lives where other antibiotics stall, but the big caveat is that there’s no robust human data on its safety for expectant mothers or their unborn babies. Animal studies don’t always tell the whole story about what happens in people. The U.S. FDA dropped its old system labeling drugs as “A, B, C, D, or X.” Instead, medicines are weighed by benefits and risks, which means discussing all the information with the prescribing doctor.
In my experience covering community health, doctors treat pregnancy as a period to stick with time-tested drugs. Drugs with a long history, like amoxicillin, often get picked over newer or less tested options. Most practitioners think very carefully before using something like cefpirome unless older antibiotics fail and the infection threatens both mother and child.
Breastfeeding mothers share everything with their baby, sometimes down to trace amounts of medication. The evidence on cefpirome entering breast milk is slim. Most medical sources sidestep this drug for new moms unless the infection leaves no room for negotiation. The old medical textbooks and databases don’t list solid data about how much—if any—cefpirome passes into breast milk, but most cephalosporins pass in low levels and rarely cause direct harm. Still, doctors stress caution and monitor for diarrhea or mouth yeast infections in infants.
From my talks with pharmacists, the usual practice asks nursing mothers to stop breastfeeding temporarily if they must take strong, newer antibiotics. Some hospitals keep a lactation expert on call to help mothers weigh risks and benefits or suggest timed feeds where medicine clears from the bloodstream before the next nursing session.
Women often find themselves torn between fighting a dangerous infection and worrying about possible drug side effects for their babies. Trust grows out of open conversations with doctors. The best practitioners don’t hand out powerful antibiotics lightly. They walk mothers through every step of treatment, giving honest info—not guarantees or absolutes—about what’s known and what isn’t.
Pharmacovigilance on medicines like cefpirome moves slowly. Pregnant and breastfeeding women rarely sign up for clinical trials by design, so safety data can feel foggy. This gap puts responsibility back on doctors and families to make careful, informed choices. Researchers and regulators need to push for better pregnancy and lactation-specific drug data rather than sidestepping tough questions. Until more evidence stacks up, the default stance keeps cefpirome as a last-resort choice in these populations.
Whenever an infection strikes during pregnancy or breastfeeding, speak directly to a doctor. Share concerns, ask about alternative treatments, and track any symptoms closely—fever, rash, changes in infant feeding, or digestive upset. Public health programs should push for accessible information so people aren’t scrambling in the dark during stressful times. At the clinic, honest back-and-forth leads to smarter, safer care for mothers and their children.
| Names | |
| Preferred IUPAC name | cefpirome sulfate |
| Other names |
Cefpirome Cefpirome sulfate Cefpirom HR 810 Cefpirome monosulfate |
| Pronunciation | /ˈsɛf.paɪˌroʊm ˈsʌl.feɪt/ |
| Identifiers | |
| CAS Number | 85721-33-1 |
| Beilstein Reference | 2113695 |
| ChEBI | CHEBI:3494 |
| ChEMBL | CHEMBL2106139 |
| ChemSpider | 21589814 |
| DrugBank | DB01413 |
| ECHA InfoCard | 100.104.977 |
| EC Number | 64091-00-1 |
| Gmelin Reference | 92790 |
| KEGG | D03575 |
| MeSH | D017978 |
| PubChem CID | 6918494 |
| RTECS number | UX8897130 |
| UNII | EF3QW0I614 |
| UN number | UN3077 |
| CompTox Dashboard (EPA) | DTXSID6049867 |
| Properties | |
| Chemical formula | C22H22N6O5S2·H2SO4 |
| Molar mass | 684.69 g/mol |
| Appearance | White to yellowish-white crystalline powder |
| Odor | Odorless |
| Density | Density: 2.14 g/cm³ |
| Solubility in water | Very soluble in water |
| log P | -2.5 |
| Acidity (pKa) | 2.6 |
| Basicity (pKb) | 6.5 |
| Magnetic susceptibility (χ) | -81.9×10⁻⁶ cm³·mol⁻¹ |
| Viscosity | Viscosity: 1.06 mPa·s (25°C, 10% solution) |
| Dipole moment | 6.49 D |
| Pharmacology | |
| ATC code | J01DE02 |
| Hazards | |
| Main hazards | May cause allergy or asthma symptoms or breathing difficulties if inhaled; may cause respiratory irritation. |
| GHS labelling | GHS07, GHS05 |
| Pictograms | GHS05,GHS07 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | Keep container tightly closed. Store in a dry place. Store in a well-ventilated place. |
| NFPA 704 (fire diamond) | Health: 2, Flammability: 0, Instability: 0, Special: - |
| Lethal dose or concentration | LD₅₀ (intravenous, mouse): 760 mg/kg |
| LD50 (median dose) | LD50 (median dose): Mouse intravenous LD50: 610 mg/kg |
| NIOSH | Not Listed |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 1-2 g every 12 hours |
| Related compounds | |
| Related compounds |
Cefpirome Cefepime Cefotaxime Ceftriaxone |
